Han Lab News


Steady strides in multiple-sclerosis therapeutics research

A team of researchers led by May Han, assistant professor of neurology and neurological sciences, have discovered a clue why some patients fail to respond to Gilenya, a therapy used to treat multiple sclerosis. 


Found: Potential new way to predict some multiple-sclerosis patients’ disease course, drug response

Stanford neurologist May Han, MD, who specializes in MS, encounters questions like these from her patients on a daily basis. MS is an autoimmune disease of the brain and spinal cord that causes paralysis, blindness and other disabling symptoms. Over a million people, most of them young adults in the prime of life, suffer from MS worldwide.


Post-doctoral position available in the Han Lab.
Please contact Dr. May Han

Neurology in the News